Precigen (PGEN) Assets Average (2013 - 2026)
Precigen (PGEN) posted quarterly Assets Average of $147.1 million for Q1 2026, up 7.33% year-over-year from $137.0 million in Q1 2025, and down 9.99% quarter-over-quarter from $163.4 million in Q4 2025.
Precigen (PGEN) Assets Average (2013 - 2026) Analysis & Trends
Precigen (PGEN) has reported Assets Average for 14 consecutive years, with $147.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 7.33% year-over-year to $147.1 million; the TTM figure through Mar 2026 stood at $147.1 million (up 7.33% YoY), while the FY2025 annual figure was $150.4 million, up 1.51% from the prior year.
- Assets Average retreated to $147.1 million in Q1 2026 per PGEN's latest filing, from $163.4 million in the prior quarter.
- Across five years, Assets Average topped out at $347.7 million in Q1 2022 and bottomed at $78.3 million in Q3 2024.
- Historically, Assets Average has averaged $186.3 million across 5 years, with a median of $163.4 million in 2025.
- Annual changes were most pronounced in 2024 — Assets Average tumbled 60.67% — and 2025, when it surged 74.39%.
- Precigen's Assets Average stood at $237.6 million in 2022, then decreased by 28.09% to $170.9 million in 2023, then tumbled by 33.06% to $114.4 million in 2024, then surged by 42.86% to $163.4 million in 2025, then fell by 9.99% to $147.1 million in 2026.
- Business Quant data shows PGEN's Assets Average at $147.1 million in Q1 2026, $163.4 million in Q4 2025, and $136.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Precigen | 2.18 Bn | 2.18 Bn | 52.17 Mn | 154.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 154.46 Mn |
| Mar 31, 2026 | 147.07 Mn |
| Dec 31, 2025 | 163.38 Mn |
| Sep 30, 2025 | 136.58 Mn |
| Jun 30, 2025 | 115.34 Mn |
| Mar 31, 2025 | 137.03 Mn |
| Dec 31, 2024 | 114.37 Mn |
| Sep 30, 2024 | 78.32 Mn |
| Jun 30, 2024 | 104.00 Mn |
| Mar 31, 2024 | 142.95 Mn |
| Dec 31, 2023 | 170.87 Mn |
| Sep 30, 2023 | 199.11 Mn |
| Jun 30, 2023 | 224.54 Mn |
| Mar 31, 2023 | 228.76 Mn |
| Dec 31, 2022 | 237.61 Mn |
| Sep 30, 2022 | 290.23 Mn |
| Jun 30, 2022 | 328.40 Mn |
| Mar 31, 2022 | 347.71 Mn |
| Dec 31, 2021 | 368.38 Mn |
| Sep 30, 2021 | 389.74 Mn |